DUBLIN, Apr. 23, 2014 /PRNewswire/ --
Research and Markets
) has announced the addition of the
report to their offering.
The analysts forecast the Global Depression Drugs market to grow at a CAGR of 2.49 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in the number of patients suffering from depression. The Global Depression Drugs market has also been witnessing the growing awareness of depression drugs. However, the generic erosion of key blockbuster drugs could pose a challenge to the growth of this market.
The report, the Global Depression Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Depression Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Increasing public awareness regarding depression and associated disorders is expected to increase the acceptability of various drugs, and thereby an increase in drug penetration. For instance, ADAP educates high school students, teachers, and parents about depression disorder. ADAP aims to increase awareness about mood disorders in young people while stressing the need for evaluation and treatment.
Similarly, the Peer-to-Peer Depression Awareness Campaign project is the student education component of the educational collaboration between the Depression Center and Ann Arbor public schools. The project aims to educate high school students about depression and depressive illnesses, and support them in finding creative ways to deliver this knowledge to their peers in order to reduce stigma, raise awareness, and help to promote the early detection of depression, bipolar disorder, and related illnesses.
According to the report, one of the main drivers in this market is the increase in the number of patients suffering from depression. The increasing aging population is contributing to the growth of the market. The number of patients suffering from depression is increasing owing to increasingly elevated stress levels, unhealthy lifestyle, and social imbalances both in developing and developed nations.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Market Segmentation by Product Types
08. Market Segmentation by Category
09. Geographical Segmentation
10. Buying Criteria
11. Rate of Incidence and Prevalence
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Vendor Landscape
18. Key Vendor Analysis
19. Other Reports in this Series
- Eli Lilly & Co.
- Forest Laboratories Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
For more information visit http://www.researchandmarkets.com/research/qbtwvc/global_depression
Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets